Design and Development of Dual Release Reconstitutable Oral Suspension of Cefpodoxime Proxetil for Pediatric Patient Using Risk-Based Quality by Design Approach-Reference-Cited by-同舟云学术

Design and Development of Dual Release Reconstitutable Oral Suspension of Cefpodoxime Proxetil for Pediatric Patient Using Risk-Based Quality by Design Approach

Published:2021-08-31 Issue: Volume: Page:
ISSN:1872-5120
Container-title:Journal of Pharmaceutical Innovation
language:en
Short-container-title:J Pharm Innov

Author:

Patel Mukesh S.,Patel Alpesh D.,Damor Shraddha

Publisher

Springer Science and Business Media LLC

Subject

Drug Discovery,Pharmaceutical Science

Link

https://link.springer.com/content/pdf/10.1007/s12247-021-09577-y.pdf

Reference32 articles.

1. Patel GC, Prajapati J, Morthana KM, Khunt DM. Formulation and evaluation of oral reconstitutable suspension of cefpodoxime proxetil. J Pharma & Drug Devel. 2015;3(2):1–7.

2. Drugupdates.com. Cefpodoxime proxetil basic information", September (2014), www.drugupdates.com

3. Mandlik S, Agarwal P, Dandgavhal HP. Implementation Of Quality By Design (Qbd) approach in formulation and development of ritonavir pellets using extrusion spheronization method. Int J Appl Pharma 2020;12(1):139–46.

4. Jain R, Singh S, Dhawan S. Dual release pharmaceutical suspension. 2011; US 10268808 Al.

5. Patel MS, Pate SS, Patel NM. Controlled release conundrum. Pharm Formulation & Quality. 2007;9(5):32–6.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quality-by-design driven approach in the formulation of an anti-ulcer and gastro-protective oral suspension;Drug Development and Industrial Pharmacy;2024-07-02

2. Risk Assessment of Subcritical Water Hydrolysis (SWH) System for Sugar Recovery using Failure Modes and Effects Analysis (FMEA) Methods;Sains Malaysiana;2022-10-31